5.5 Labeling of Dispensed Drugs
Key Takeaways
- 49 Pa. Code § 27.18(d) requires eight label elements: pharmacy name/address, Rx number, dispensing date, patient name, prescriber name, directions, drug name/strength, and beyond-use date.
- The dispensing date (not the written date) must appear; "Take as directed" is not acceptable as the sig.
- FDA Medication Guides under 21 CFR § 208 must be handed to the patient on every dispensing event, new or refill.
- PPPA child-resistant packaging is required unless a statutory exemption applies (single OTC dose, prescriber/patient written request, SLIDs); PA does not add a stricter state floor.
- PA's counseling-offer rule (49 Pa. Code § 27.31) is stricter than OBRA '90 — every patient, every new prescription, must be offered counseling.
Why Labeling Matters on the MPJE
A dispensing label is the patient's primary safety net — and an MPJE favorite because PA rules layer on top of federal ones. The PA State Board of Pharmacy enforces 49 Pa. Code § 27.18(d), which enumerates the mandatory label elements. A pharmacist who dispenses with an incomplete label is dispensing a misbranded drug under both the FDCA (21 USC § 353) and the PA Controlled Substance, Drug, Device and Cosmetic Act (35 P.S. §§ 780-101 et seq.), exposing the pharmacy to Board discipline and the permit to revocation. On the exam, an answer that omits any one element — most commonly the beyond-use date or the drug name/strength — is wrong.
The Eight Required Label Elements
49 Pa. Code § 27.18(d) requires the following on every dispensed prescription container's label:
| # | Required element | Notes |
|---|---|---|
| 1 | Pharmacy name and address | The address of the actual dispensing location; chain stores may not substitute a corporate headquarters. |
| 2 | Prescription (Rx) number | Unique serial number assigned by the dispensing pharmacy for refills and records. |
| 3 | Date of dispensing | The date actually dispensed, not the prescription's written date. |
| 4 | Patient's name | Full name; initials alone are not acceptable. |
| 5 | Prescriber's name | The authorized practitioner who issued the prescription. |
| 6 | Directions for use | "Sig" — must be patient-readable; abbreviations may not appear on the dispensed label. |
| 7 | Drug name and strength | If generic, the manufacturer's or distributor's name must also appear per 21 CFR § 207.25. |
| 8 | Beyond-use date | Patient-use expiration, distinct from manufacturer expiration. |
PA also requires that any auxiliary labels deemed clinically necessary (e.g., "May cause drowsiness," "Take with food," "Shake well," "Avoid sunlight") be affixed. The pharmacist-manager (§ 27.11) is responsible for ensuring that auxiliary-label use reflects current package-insert and USP DI guidance.
Auxiliary Labels and Patient Counseling
Auxiliary labels are required whenever the drug's labeling warns of a clinically significant hazard. Under PA's counseling-offer rule (49 Pa. Code § 27.31, stricter than OBRA '90's Medicaid-only floor), the pharmacist must offer to counsel every patient (or caregiver) on every new prescription. Counseling must cover directions, common side effects, storage, and special precautions. The counseling offer is part of the "labeling" concept on the MPJE — a complete sticker is not a substitute for the oral offer.
Medication Guides
FDA Medication Guides (21 CFR § 208) are paper handouts that must be dispensed with certain drugs (e.g., NSAIDs, antidepressants, anticoagulants, isotretinoin). The pharmacist must hand the Guide to every patient receiving the drug on every dispensing event (new or refill) and confirm the patient receives it — leaving it in the bag is not enough. A pharmacy that consistently fails to pass Medication Guides is dispensing a misbranded drug. The iPLEDGE REMS for isotretinoin carries additional labeling and dispensing requirements (see § 5.7).
Child-Resistant Packaging and PPPA Exemptions
The Poison Prevention Packaging Act (PPPA) (15 USC § 1471 et seq.; implementing regulations at 16 CFR § 1700) requires child-resistant (CR) packaging for most household drugs. CR packaging must be "significantly difficult for children under 5 to open" but easy for adults. Senior-friendly packaging is permitted only when it still meets CR performance standards — it is not a substitute.
PPPA exemptions (MPJE favorites):
- Prescriber or patient request. The prescriber may request non-CR, or the patient (or caregiver) may sign a written request; the pharmacy must document the request.
- Single OTC dose. A single OTC dose packaged in a non-reclosable form (e.g., one blister pill) is exempt.
- Special Packaging Identifying Devices (SLIDs). Certain ID-style packaging.
- Emergency contraception packaged in a single course-of-treatment OTC format.
PA does not add state-level CR rules stricter than the PPPA — the federal floor controls.
Generic Label Equivalence
When a generic is dispensed under PA's drug-product-selection rules (49 Pa. Code § 27.31), the label must identify the dispensed drug by its generic name and the manufacturer. The label may also show the brand name (e.g., "Amoxicillin 500 mg (Amoxil)") so patients can correlate with prior fills, but the dispensed product's identity must be unambiguous. The pharmacist must pass any lower acquisition cost on to the patient or payer when substituting. Falsely labeling a generic as a brand is misbranding under FDCA § 502.
Common MPJE Traps
- A label showing the prescription's written date instead of the dispensing date fails § 27.18(d).
- "Take as directed" alone is not acceptable directions — the sig must be patient-readable.
- A refill carrying the original Rx's label without an updated beyond-use date fails.
- The counseling offer must be made even if the patient declines — silent default is not a valid offer.
- Failing to hand the Medication Guide on a refill is the same violation as failing on a new prescription.
Which of the following is NOT a required label element under 49 Pa. Code § 27.18(d) for a dispensed prescription in PA?
A patient requests non-child-resistant packaging for their prescription. Under the PPPA framework that PA adopts, which statement is correct?
Which action is required for a drug that carries an FDA-approved Medication Guide under 21 CFR § 208?